What’s new series: Drug Therapy Updates

In this episode of TransplantRPh, April discusses the latest updates in drug therapy, including advancements in treatments for hepatitis C, intracerebral hemorrhage, food allergies, eosinophilic esophagitis, paroxysmal nocturnal hemoglobinuria, chronic lymphocytic leukemia, chronic inflammatory demyelinating polyneuropathy, and Duchenne muscular dystrophy. Connect with April on LinkedIn at April Oliveros, YouTube at Pharmacist April, Instagram at PharmacistApril, or via email at aprilfortinoliveros@gmail.com. Don’t miss her new e-book providing a step-by-step guide for foreign pharmacy graduates on becoming pharmacists in the USA! Detailed Notes: - Cost-Effectiveness of Treating Hepatitis C Virus Infection During Childhood: Early intervention saves nearly $50,000 in lifetime healthcare costs. - Reversal Strategy for Intracerebral Hemorrhage:Andexanet alfa shows higher rates of hemostasis but with increased thrombotic risk. - Omalizumab for Food Allergy: Approved for reducing allergic reactions to multiple foods, requires regular injections. - Benralizumab for Eosinophilic Esophagitis: Achieves higher rates of histologic remission, need for more biomarkers. - Iptacopan for Paroxysmal Nocturnal Hemoglobinuria: Reduces transfusion needs, risk of serious infections. - CAR-T Cell Therapy for Multiply Relapsed CLL: Approved for patients after two or more lines of therapy. - Efgartigimod Alfa-Hyaluronidase in CIDP: Shows significant improvement in symptoms and lower rates of clinical deterioration. - Givinostat for Duchenne Muscular Dystrophy: Slows disease progression, particularly in the four-stair climb test.